HomeCompareVRRMW vs ABBV

VRRMW vs ABBV: Dividend Comparison 2026

VRRMW yields 26.53% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VRRMW wins by $5.8K in total portfolio value
10 years
VRRMW
VRRMW
● Live price
26.53%
Share price
$7.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$108.1K
Annual income
$12,843.31
Full VRRMW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VRRMW vs ABBV

📍 VRRMW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVRRMWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VRRMW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VRRMW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VRRMW
Annual income on $10K today (after 15% tax)
$2,254.64/yr
After 10yr DRIP, annual income (after tax)
$10,916.81/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $10,139.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VRRMW + ABBV for your $10,000?

VRRMW: 50%ABBV: 50%
100% ABBV50/50100% VRRMW
Portfolio after 10yr
$105.2K
Annual income
$18,807.54/yr
Blended yield
17.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VRRMW
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
1.3
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VRRMW buys
0
ABBV buys
0
No recent congressional trades found for VRRMW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVRRMWABBV
Forward yield26.53%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$108.1K$102.3K
Annual income after 10y$12,843.31$24,771.77
Total dividends collected$70.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: VRRMW vs ABBV ($10,000, DRIP)

YearVRRMW PortfolioVRRMW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$13,353$2,652.52$11,550$430.00+$1.8KVRRMW
2$17,597$3,310.08$13,472$627.96+$4.1KVRRMW
3$22,906$4,076.96$15,906$926.08+$7.0KVRRMW
4$29,469$4,959.72$19,071$1,382.55+$10.4KVRRMW
5$37,495$5,963.37$23,302$2,095.81+$14.2KVRRMW
6$47,211$7,091.17$29,150$3,237.93+$18.1KVRRMW
7$58,861$8,344.52$37,536$5,121.41+$21.3KVRRMW
8$72,704$9,722.92$50,079$8,338.38+$22.6KVRRMW
9$89,017$11,223.93$69,753$14,065.80+$19.3KVRRMW
10$108,091$12,843.31$102,337$24,771.77+$5.8KVRRMW

VRRMW vs ABBV: Complete Analysis 2026

VRRMWStock

Verra Mobility Corporation provides smart mobility technology solutions and services in the United States, Australia, Canada, and Europe. It operates through three segments: Commercial Services; Government Solutions; and Parking Solutions. The Government Solutions segment offers automated safety solutions, including services and technologies that enable photo enforcement through road safety camera programs, which detects and process traffic violations related to red light, speed, school bus, and city bus lanes. This segment serves municipalities, counties, school districts, and law enforcement agencies. The Commercial Services segment provides automated toll and violations management, and title and registration services to rental car companies, fleet management companies, and other large fleet owners. The Parking Solutions segment provides an integrated suite of parking software and hardware solutions to universities, municipalities, parking operators, healthcare facilities, and transportation hubs. The company was incorporated in 2016 and is headquartered in Mesa, Arizona.

Full VRRMW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VRRMW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VRRMW vs SCHDVRRMW vs JEPIVRRMW vs OVRRMW vs KOVRRMW vs MAINVRRMW vs JNJVRRMW vs MRKVRRMW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.